Literature DB >> 16015676

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

Paul C Lambert1, Alex J Sutton, Paul R Burton, Keith R Abrams, David R Jones.   

Abstract

There has been a recent growth in the use of Bayesian methods in medical research. The main reasons for this are the development of computer intensive simulation based methods such as Markov chain Monte Carlo (MCMC), increases in computing power and the introduction of powerful software such as WinBUGS. This has enabled increasingly complex models to be fitted. The ability to fit these complex models has led to MCMC methods being used as a convenient tool by frequentists, who may have no desire to be fully Bayesian. Often researchers want 'the data to dominate' when there is no prior information and thus attempt to use vague prior distributions. However, with small amounts of data the use of vague priors can be problematic. The results are potentially sensitive to the choice of prior distribution. In general there are fewer problems with location parameters. The main problem is with scale parameters. With scale parameters, not only does one have to decide the distributional form of the prior distribution, but also whether to put the prior distribution on the variance, standard deviation or precision. We have conducted a simulation study comparing the effects of 13 different prior distributions for the scale parameter on simulated random effects meta-analysis data. We varied the number of studies (5, 10 and 30) and compared three different between-study variances to give nine different simulation scenarios. One thousand data sets were generated for each scenario and each data set was analysed using the 13 different prior distributions. The frequentist properties of bias and coverage were investigated for the between-study variance and the effect size. The choice of prior distribution was crucial when there were just five studies. There was a large variation in the estimates of the between-study variance for the 13 different prior distributions. With a large number of studies the choice of prior distribution was less important. The effect size estimated was not biased, but the precision with which it was estimated varied with the choice of prior distribution leading to varying coverage intervals and, potentially, to different statistical inferences. Again there was less of a problem with a larger number of studies. There is a particular problem if the between-study variance is close to the boundary at zero, as MCMC results tend to produce upwardly biased estimates of the between-study variance, particularly if inferences are based on the posterior mean. The choice of 'vague' prior distribution can lead to a marked variation in results, particularly in small studies. Sensitivity to the choice of prior distribution should always be assessed. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015676     DOI: 10.1002/sim.2112

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  118 in total

Review 1.  Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Authors:  Christine M Nguyen; Mark Bounthavong; Margaret A S Mendes; Melissa L D Christopher; Josephine N Tran; Rashid Kazerooni; Anthony P Morreale
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

2.  Temporal patterns, heterogeneity, and stability of diurnal cortisol rhythms in children with autism spectrum disorder.

Authors:  Andrew J Tomarken; Gloria T Han; Blythe A Corbett
Journal:  Psychoneuroendocrinology       Date:  2015-08-21       Impact factor: 4.905

3.  A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.

Authors:  Pepijn Vemer; Maiwenn J Al; Mark Oppe; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

4.  Equity in specialist waiting times by socioeconomic groups: evidence from Spain.

Authors:  Ignacio Abásolo; Miguel A Negrín-Hernández; Jaime Pinilla
Journal:  Eur J Health Econ       Date:  2013-08-02

5.  A Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL.

Authors:  Stephen Brown; Brian Hutton; Tammy Clifford; Doug Coyle; Daniel Grima; George Wells; Chris Cameron
Journal:  Syst Rev       Date:  2014-09-29

6.  A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes.

Authors:  Thomas Pa Debray; Johanna Aag Damen; Richard D Riley; Kym Snell; Johannes B Reitsma; Lotty Hooft; Gary S Collins; Karel Gm Moons
Journal:  Stat Methods Med Res       Date:  2018-07-23       Impact factor: 3.021

Review 7.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Daniel J A Devoe; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

8.  Is It Necessary to Perform the Pharmacological Interventions for Intrahepatic Cholestasis of Pregnancy? A Bayesian Network Meta-Analysis.

Authors:  Yi Shen; Jie Zhou; Sheng Zhang; Xu-Lin Wang; Yu-Long Jia; Shu He; Yuan-Yuan Wang; Wen-Chao Li; Jian-Guo Shao; Xun Zhuang; Yuan-Lin Liu; Gang Qin
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

9.  The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms.

Authors:  C Elizabeth McCarron; Eleanor M Pullenayegum; Lehana Thabane; Ron Goeree; Jean-Eric Tarride
Journal:  BMC Med Res Methodol       Date:  2010-07-09       Impact factor: 4.615

10.  A re-evaluation of random-effects meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson; David J Spiegelhalter
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-01       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.